NCT02656563View on ClinicalTrials.gov

Radium 223 Following Intermittent ADT

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions

Prostate Cancer

Interventions

RADIATION

Radium 223 Dichloride (Xofigo®)

Radium 223 Dichloride (Xofigo®) monthly for six months

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Canadian Urology Research Consortium

OTHER

NCT02656563 - Radium 223 Following Intermittent ADT | Biotech Hunter | Biotech Hunter